Used in targeted cancer therapies, particularly for tumors overexpressing IGF-1R, such as certain breast, lung, and colorectal cancers. This antibody blocks the insulin-like growth factor 1 receptor (IGF-1R), inhibiting downstream signaling pathways that promote tumor cell proliferation, survival, and metastasis. It can induce receptor internalization and degradation, reducing cell surface receptor availability. Often employed in antibody-drug conjugates (ADCs) or as a component in bispecific antibodies to enhance anti-tumor efficacy. Also utilized in diagnostic and research settings to detect IGF-1R expression in tumor tissues. Its high specificity makes it valuable in developing personalized treatment strategies targeting the IGF axis.